Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio

Core Insights - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is recognized as one of the seven cheap pharmaceutical stocks to consider for investment according to hedge funds [1] - The company has received a price target increase from Truist Securities, reflecting confidence in its pain management portfolio and ongoing product momentum [2] Financial Outlook - Collegium expects net product revenue for the year 2026 to be between $805 million and $825 million, with Jornay PM projected to contribute at least $190 million to $200 million [3] - The adjusted EBITDA is anticipated to range from $455 million to $475 million, indicating strong profitability and effective cost management [3] Business Focus - Collegium is focused on developing and commercializing innovative pain management therapies, including abuse-deterrent opioid formulations, aimed at improving patient safety and treatment outcomes [4]